Pfizer Highlights Oncology Innovation and Advances in Next-Generation Pipeline at ASCO 2026 Pfizer Inc. (NYSE: PFE) has announced an extensive and data-rich presence at the American Society of Clinical Oncology…
Genentech’s Enspryng (Satralizumab) Cuts Relapse Risk by 68%, Showing Promise as a Potential First Treatment for MOGAD Genentech, a member of the Roche Group, has announced compelling new results from…
Donor Funding Drives $15M Initiative Supporting 62 Researchers Focused on Alzheimer’s, Macular Degeneration, and Glaucoma The BrightFocus Foundation has announced a major new investment of $15.2 million in research grants…
AHF Initiates Statewide Campaign Calling for Full Reinstatement of Florida’s AIDS Drug Assistance Program The AIDS Healthcare Foundation (AHF) has launched a statewide public awareness campaign urging Ron DeSantis and…
Agenus to Showcase Initial Phase 2 Botensilimab Results in Advanced Cutaneous Melanoma at ASCO 2026 Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing next-generation cancer immunotherapies, announced…
Real Time Medical Systems Highlights New Leadership, AI Solutions, and Expanded Partnership at NAACOS Spring 2026 Real Time Medical Systems (Real Time), a KLAS-rated and HITRUST R2 Certified leader in…
n-Lorem Foundation Reaches Key Milestone with 50th Nano-Rare Patient Treated Using a Personalized Antisense Oligonucleotide Therapy n-Lorem, a nonprofit foundation dedicated to advancing precision genetic medicine for individuals with ultra-rare…
U.S. Food and Drug Administration Accepts Filing for Genentech’s Gazyva Targeting the Most Prevalent Form of Lupus Genentech, a member of the Roche Group, has announced a major regulatory milestone…
Wound Healing Society Acknowledges Eluciderm, Inc. with Industrial R&D Award for Advancing ELU42 Mechanism of Action Research Eluciderm, Inc., a clinical-stage biopharmaceutical organization focused on the development of innovative small-molecule…
Annals of Internal Medicine Reports One-Year Findings from LivaNova’s OSPREY Clinical Trial in Obstructive Sleep Apnea LivaNova PLC (Nasdaq: LIVN) has announced the publication of comprehensive 12-month results from its…
Entos Pharmaceuticals and L-CMD Research Foundation Join Forces to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy Entos Pharmaceuticals Inc has announced a strategic collaboration with the L-CMD Research Foundation…
Speak Foundation Introduces Patient-Led National LGMD Centers of Excellence to Drive Clinical Trials and Innovative Treatments Speak Foundation has announced the launch of a major new initiative aimed at transforming…